The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.
left ventricular ejection fraction (LVEF)≥50%；
N-terminal pro-b type natriuretic peptide (NT-proBNP)>220pg/ml or b type natriuretic peptide (BNP) >80 pg/ml;
symptoms and syndromes of heart failure;
At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).
Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.
Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;
Severe arrhythmia;
Severe primary cardiac valvular disease;
This study is a prospective study with HFpEF patients, diagnosed based on 2016 and 2019 European Society of Cardiology (ESC) concensus. The inclusion criteria include left ventricular ejection fraction (LVEF)≥50%；N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml; symptoms and syndromes of heart failure; and at least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities. We exclude patients with special cardiomyopathy, ; Infarction, myocardial fibrosis caused by ischemic cardiomyopathyand acute coronary syndrome; Severe arrhythmia; Severe primary cardiac valvular disease; Restrictive pericardial disease; Refuse to participate in the study.
Cohort
Prospective
Not listed
All-cause Death
Rate or number of All-cause Death
Cardiovascular Death
Rate or number of Cardiovascular Death
Hospitalization Due to Heart Failure
Rate or number of Hospitalization Due to Heart Failure
Implantable cardioverter-defibrillator Implantation
Rate or number of Implantable cardioverter-defibrillator Implantation
Heart Transplantation Heart Transplantation
Rate or number of Heart Transplantation
Pacemaker Implantation
Rate or number of Pacemaker Implantation
Atrial fibrillation
Rate or number of Atrial fibrillation
Click on the lead sponsor to view all of their trials.
